[1] Marshall S, Hujer A M, Rojas L J,et al. Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in enterobacteriaceae?[J].Antimicrob Agents Chemother,2017,61(4):eco2243-16.
[2] Zou C,Wei J, Shan B, et al. In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against carbapenem-resistant enterobacteriaceae isolates collected from three secondary hospitals in southwest china between 2018 and 2019[J]. Infect Drug Resist,2020,12(13):3563-3568.
[3] 林 琳,肖晓光,王 楠,等. 阿维巴坦联合头孢他啶或氨曲南对耐碳青霉烯肠杆菌科细菌体外抗菌活性研究[J].中华医院感染学杂志,2020,30(1):15-19.
[4] Mojica M F, Ouellette C P, Leber A, et al. successful treatment of bloodstream infection due to metallo-β-lactamase-producing stenotrophomonasmaltophilia in a renaltransplant patient[J].Antimicrob Agents Chemother,2016,60(9):5130-5134.
[5] Benchetrit L, Mathy V, Armand L L, et al. Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases[J].Int J Antimicrob Agents,2020,55(1):105842.
[6] Cairns K A, Hall V, Martin G E, et al. Treatment of invasive IMP-4 Enterobacter cloacae infection in transplant recipients using ceftazidime/avibactam with aztreonam: a case series and literature review[J]. Transpl Infect Dis,2021,23(2):e13510.
[7] Yasmin M, Fouts D E, Jacobs M R, et al. Monitoring ceftazidime-avibactam and aztreonam concentrations in the treatment of a bloodstream infection caused by a multidrug-resistant enterobacter sp. carrying both klebsiella pneumoniae carbapenemase-4 and new delhimetallo-β-lactamase-1[J]. Clin Infect Dis,2020,71(4):1095-1098.
[8] Falcone M, Daikos G L, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-β-lactamase-producing enterobacterales[J]. Clin Infect Dis,2021,72(11):1871-1878.
[9] Paul M, Daikos G L, Durante M E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial[J]. Lancet Infect Dis,2018,18(4):391-400.
[10] Motsch J, Murta C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections[J]. Clin Infect Dis,2020,70(9):1799-1808.
[11] Li J, Lovern M, Green M L, et al. Ceftazidime-avibactam population pharmacokinetic modeling and pharmacodynamic target attainment across adult indications and patient subgroups[J]. Clin Transl Sci,2019,12(2):151-163.
[12] Cornely O A, Cisneros J M, Torre C J, et al. Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study[J]. J Antimicrob Chemother,2020,75(3):618-627.
[13] Lodise T P, Smith N M, O'Donnell N, et al. Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing enterobacteriaceae using a hollow-fibre infection model[J]. J Antimicrob Chemother,2020,75(9):2622-2632.
[14] Li P, Lin Y, Hu X, et al. Characterization of blaNDM-1-and blaSHV-12-Positive IncX3 Plasmid in an enterobacter hormaechei new sequence type 1000 from china[J]. Infect Drug Resist,2020,13:145-153.
[15] 张 梅,谢祥红,魏文波,等.武警某部医院碳青霉烯耐药肺炎克雷伯菌的耐药基因分析[J].武警医学,2021,32,(1):38-41.
[16] Yin D, Lin Y, Li Z, et al. Characterization of a Novel NDM-5-harboring plasmid from a carbapenem-resistant escherichia coli isolate from china[J]. Infect Drug Resist,2020,13:3929-3935.